Biodegradable polymeric nanoparticles based drug delivery systems

Colloids and Surfaces B: Biointerfaces

Volumn 75, Issue 1, 2010, Pages 1-18

  Kumari, Avnesh ^a   Yadav, Sudesh Kumar ^a   Yadav, Subhash C ^a  

^a CSIR INSTITUTE OF HIMALAYAN BIORESOURCE TECHNOLOGY   (India)

Author keywords

Biodegradable; Chitosan; Encapsulation efficiency; Poly caprolactone; Polylactic acid; Polylactic acid co glycolic acid; Polymeric nanoparticles

Indexed keywords

CAPROLACTONE; ENCAPSULATION EFFICIENCY; GLYCOLIC ACIDS; POLY LACTIC ACID; POLYMERIC NANOPARTICLES;

ACIDS; BIOCHEMISTRY; CHITIN; CHITOSAN; DRUG DELIVERY; ENCAPSULATION; NANOPARTICLES;

BIODEGRADABLE POLYMERS;

AMPHOTERICIN B; BOVINE SERUM ALBUMIN; CHITOSAN; CISPLATIN; CLONAZEPAM; CYANOACRYLATE DERIVATIVE; CYCLOSPORIN A; DEXAMETHASONE; ESTRADIOL; GELATIN; GLYCYRRHIZIC ACID; HALOPERIDOL; INSULIN; NANOCARRIER; OLIGONUCLEOTIDE; ORIDONIN; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; PROGESTERONE; ROSE BENGAL; RUBITECAN; SAVOXEPINE; TAMOXIFEN; TETANUS TOXOID; TRIPTORELIN; TYRPHOSTIN; UNINDEXED DRUG; XANTHONE DERIVATIVE;

ACUTE PSYCHOSIS; ALZHEIMER DISEASE; APLASTIC ANEMIA; BACTERIAL MENINGITIS; BILIARY CIRRHOSIS; BIODEGRADABILITY; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; CROHN DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HUMAN; LEISHMANIASIS; MELANOMA; MENOPAUSAL SYNDROME; MOLECULAR WEIGHT; MYASTHENIA GRAVIS; NANOENCAPSULATION; NANOTECHNOLOGY; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SOLID TUMOR; SURFACE PROPERTY; TETANUS; ULCERATIVE COLITIS; VOMITING;

BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS; SURFACE PROPERTIES;

EID: 70450221930     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2009.09.001     Document Type: Review

References (131)

1. Perelshtein I., et al. Sonochemical coating of silver nanoparticles on textile fabrics (nylon, polyester and cotton) and their antibacterial activity. Nanotechnology 19 (2008) 245705
2. Speiser B. Nanoparticles in organic production?. Issues and Opinions, 16th IFOAM Organic World Congress. Modena, Italy (2008)
3. Lai F., et al. Artemisia arborescens L essential oil loaded, solid lipid nanoparticles for potential agricultural application: preparation and characterization. AAPS Pharm. Sci. Tech. 7 1 (2006) E2
4. Huang D., et al. Plastic compatible low resistance printable gold nanoparticle conductors for flexible electronics. J. Electrochem. Soc. 150 (2003) G412
5. Choi M.J., et al. Metal-containing nanoparticles and nano-structured particles in fingermark detection. Forensic Sci. Int. 179 2-3 (2008) 87-97
6. Liu T.M., et al. Nanoparticle Electric Propulsion for Space Exploration in Space Technology and Applications International Forum (2007), STAIF
7. Bender A.R., et al. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 6 (1996) 1467-1471
8. Bonduelle S., et al. Association of cyclosporin to isohexylcyanoacrylate nanospheres and subsequent release in human plasma in vitro. J. Microencapsul. 9 2 (1992) 173-182
9. Jahanshahi M., and Babaei Z. Protein nanoparticle: a unique system as drug delivery vehicles. Afr. J. Biotech. 7 (2008) 4926
10. Kawashima Y., et al. Mucoadhesive d,l-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 5 1 (2000) 77-85
11. Rieux A.D., et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006) 1
12. Shenoy D.B., and Amiji M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm. 293 1-2 (2005) 261-270
13. Glen A. The impact of nanotechnology in drug delivery: global developments. Market Anal. Future Prospects (2005). http://www.nanomarkets.com/ Available from: http://www.nanomarkets.com (cited 31.03.09).
14. 2. Ann. Oncol. 11 8 (2000) 1029-1033
15. Schroeder U., et al. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87 11 (1998) 1305-1307
16. Raghuvanshi R.S., et al. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int. J. Pharm. 245 1-2 (2002) 109-121
17. Kreutera J., et al. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49 (1997) 81
18. Fassas A., et al. Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br. J. Haematol. 122 1 (2003) 161-163
19. Jean-Christophe L., et al. Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J. Control. Release 39 (1996) 339
20. Alexis F., et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5 4 (2008) 505-515
21. Budhian A., Siegel S.J., and Winey K.I. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J. Microencapsul. 22 7 (2005) 773-785
22. Gomez-Gaete C., et al. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 331 2 (2007) 153-159
23. Cheng Q., et al. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm. Drug Disposition 29 (2008) 431
24. Mu L., and Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 86 1 (2003) 33-48
25. Coester C., et al. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int. J. Pharm. 196 2 (2000) 147-149
26. Damge C., Maincent P., and Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117 2 (2007) 163-170
27. Date A.A., Joshi M.D., and Patravale V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59 6 (2007) 505-521
28. Calvo P., et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods 111 2 (2001) 151-155
29. Ahmad Z., et al. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J. Chest Dis. Allied Sci. 48 3 (2006) 171-176
30. Kim S.Y., and Lee Y.M. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. Biomaterials 22 13 (2001) 1697-1704
31. Lee K.S., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108 2 (2008) 241-250
32. Vlerken L.E.v., Vyas T.K., and Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Phama. Res. 24 (2007) 1405
33. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56 11 (2004) 1649-1659
34. Feng S.S. Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev. Med. Devices 1 1 (2004) 115-125
35. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 5 (2002) 631-651
36. Zambaux M.F., et al. Preparation and characterization of protein C-loaded PLA nanoparticles. J. Control. Release 60 2-3 (1999) 179-188
37. Soppimath K.S., et al. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 1-2 (2001) 1-20
38. Hans M.L.a.A.M.L. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6 (2002) 319
39. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ. J. 11 (2003) 51
40. Mundargi R.C., et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release 125 3 (2008) 193-209
41. Leo E., et al. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int. J. Pharm. 278 1 (2004) 133-141
42. Pinto Reis C., et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2 1 (2006) 8-21
43. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 3 (2003) 329-347
44. Kreuter J. In: Kreuter J. (Ed). Colloidal Drug Delivery Systems (1994), Marcel Dekker
45. Alonso M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58 3 (2004) 168-172
46. Sahana D.K., et al. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J. Pharm. Sci. 97 4 (2008) 1530-1542
47. Barichello J.M., et al. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 25 4 (1999) 471-476
48. Bittner B., et al. Bovine serum albumin loaded poly(lactide-co-glycolide) microspheres: the influence of polymer purity on particle characteristics. J. Microencapsul. 15 4 (1998) 495-514
49. Carrasquillo K.G., et al. Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. J. Control. Release 76 3 (2001) 199-208
50. Johansen P., et al. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 15 7 (1998) 1103-1110
51. Kumar M.N., et al. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J. Nanosci. Nanotechnol. 4 8 (2004) 990-994
52. Mittal G., et al. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Release 119 1 (2007) 77-85
53. Liu L., et al. Pectin/poly(lactide-co-glycolide) composite matrices for biomedical applications. Biomaterials 25 16 (2004) 3201-3210
54. Hedberg E.L., et al. In vivo degradation of porous poly(propylene fumarate)/poly(dl-lactic-co-glycolic acid) composite scaffolds. Biomaterials 26 22 (2005) 4616-4623
55. Patil S.D., Papadimitrakopoulos F., and Burgess D.J. Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diab. Technol. Ther. 6 6 (2004) 887-897
56. Wang L., et al. Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(d,l-lactide-co-glycolide) blend microspheres fabricated by spray drying. Biomaterials 25 16 (2004) 3275-3282
57. Di Toro R., Betti V., and Spampinato S. Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(dl-lactide-co-glycolide) copolymers. Eur. J. Pharm. Sci. 21 2-3 (2004) 161-169
58. Panyam J., et al. Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16 10 (2002) 1217-1226
59. Nobs L., et al. Poly(lactic acid) nanoparticles labeled with biologically active neutravidin for active targeting. Eur. J. Pharm. Biopharm. 58 3 (2004) 483-490
60. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58 14 (2006) 1532-1555
61. Derakhshandeh K., Erfan M., and Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur. J. Pharm. Biopharm. 66 1 (2007) 34-41
62. Wang Y.M., et al. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem. Pharm. Bull. (Tokyo) 44 10 (1996) 1935-1940
63. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83 2 (2002) 273-286
64. Rosenberg B. Fundamental studies with cisplatin. Cancer 55 10 (1985) 2303-2306
65. Avgoustakis K., et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release 79 1-3 (2002) 123-135
66. Pinto M.M., and Sousa E.P. Natural and synthetic xanthonolignoids: chemistry and biological activities. Curr. Med. Chem. 10 1 (2003) 1-12
67. Teixeira M., et al. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur. J. Pharm. Biopharm. 59 3 (2005) 491-500
68. Redhead H.M., Davis S.S., and Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Control. Release 70 3 (2001) 353-363
69. Nicoli S., et al. Design of triptorelin loaded nanospheres for transdermal iontophoretic administration. Int. J. Pharm. 214 1-2 (2001) 31-35
70. Kumar P.S., et al. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles. Pharmazie 61 7 (2006) 613-617
71. Fessi H. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989) R1-R4
72. Volz H.P., et al. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 252 2 (2002) 76-80
73. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6 14 (1992) 3275-3282
74. Fishbein I., et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release 65 1-2 (2000) 221-229
75. Matsumoto J., et al. Preparation of nanoparticles consisted of poly(l-lactide)-poly(ethylene glycol)-poly(l-lactide) and their evaluation in vitro. Int. J. Pharm. 185 1 (1999) 93-101
76. Ikezoe T., et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol. Cancer Ther. 4 4 (2005) 578-586
77. Xing J., Zhang D., and Tan T. Studies on the oridonin-loaded poly(d,l-lactic acid) nanoparticles in vitro and in vivo. Int. J. Biol. Macromol. 40 2 (2007) 153-158
78. Gao H., et al. Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-beta-cyclodextrin and its properties as the new carrier of protein delivery system. J. Control. Release 107 1 (2005) 158-173
79. Changyong C., Chae S.Y., and Jae-Won N. Thermosensitive poly(N-isopropylacrylamide)-b-poly(ε-caprolactone) nanoparticles for efficient drug delivery system. Polymer 47 (2006) 4571
80. Espuelas M.S., et al. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J. Drug Target 10 8 (2002) 593-599
81. Calvo P., et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carrier. J. Appl. Poly. Sci. 63 (1997) 125-132
82. Pan Y., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249 1-2 (2002) 139-147
83. Janes K.A., et al. Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73 2-3 (2001) 255-267
84. Bodmeier R., Chen H.G., and Paeratakul O. A novel approach to the oral delivery of micro- or nanoparticles. Pharm. Res. 6 5 (1989) 413-417
85. Maitra, A.N., et al., Process for the preparation of highly monodispersed hydrophilicpolymeric nanoparticles of size less than 100 nm, 1999, USA (US patent no. 5847111, Feb 23, 1999).
86. Erbacher P., et al. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm. Res. 15 9 (1998) 1332-1339
87. Atherden L.M. Studies with glycyrrhetic acid; inhibition of metabolism of steroids in vitro. Biochem. J. 69 1 (1958) 75-78
88. Wu Y., et al. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int. J. Pharm. 295 1-2 (2005) 235-245
89. Sarmento B., et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24 12 (2007) 2198-2206
90. De Campos A.M., Sanchez A., and Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224 1-2 (2001) 159-168
91. Oppenhiem R.C. Paclitaxel loaded gelatin nanoparticles for intravesical bladder cancer therapy. Int. J. Pharm. 8 (1981) 217
92. Li J.K., Wang N., and Wu X.S. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J. Microencapsul. 15 2 (1998) 163-172
93. Lu Z., et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 10 (2004) 7677
94. Jan Zillies C.C. Evaluating gelatin based nanoparticles as a carrier system for double stranded oligonucleotides. J. Pharm. Pharmaceut. Sci. 7 4 (2004) 17
95. Kaur A., Jain S., and Tiwary A.K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 58 1 (2008) 61-74
96. Bajpai A.K., and Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J. Mater. Sci. Mater. Med. 17 4 (2006) 345-358
97. Davis S. Drug delivery systems. Interdisciplinary Sci. Rev. 25 (2000) 175
98. Couvreur P., et al. Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carrier Syst. 19 2 (2002) 99-134
99. Seijoa B., et al. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 62 (1990) 1
100. Gürsoy A., et al. Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation. Int. J. Pharm. 52 (1989) 101
101. Gulyaev A.E., et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 10 (1999) 1564-1569
102. Arias J.L., et al. Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. Int. J. Pharm. 337 1-2 (2007) 282-290
103. Storma G., Belliota S.O., and Lasicc T.D.D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17 (1995) 31
104. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 1 (2006) 93-102
105. Torchilin V.P., and Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 16 (1995) 141
106. Stolnik S., Illum L., and Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 16 (1995) 195
107. Tobio M., et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerfaces 18 3-4 (2000) 315-323
108. Shah L.K., and Amiji M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 11 (2006) 2638-2645
109. Potineni A., et al. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J. Control. Release 86 2-3 (2003) 223-234
110. Alyautdin R.N., et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15 1 (1998) 67-74
111. Borchard G., et al. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110 (1994) 29
112. Lemarchand C., et al. Physico-chemical characterization of polysaccharide-coated nanoparticles. J. Control. Release 108 1 (2005) 97-111
113. Lee S.H., Zhang Z., and Feng S.S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 28 11 (2007) 2041-2050
114. Rodrigues J.S., et al. Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. J. Control. Release 92 1-2 (2003) 103-112
115. Cho C.S., et al. Simple preparation of nanoparticles coated with carbohydrate-carrying polymers. Biomaterials 18 4 (1997) 323-326
116. Ringe K., Walz C., and Sabel B. Nanoparticle drug delivery to the brain. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology vol. 7 (2004), American Scientific Publishers, New York
117. Chen Y., Mohanraj V.J., and Parkin J.E. Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. Lett. Peptide Sci. 10 (2003) 627
118. Danhier F., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release 133 1 (2009) 11-17
119. Esmaeili F., et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target 16 5 (2008) 415-423
120. Labhasetwar V., et al. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J. Pharm. Sci. 87 10 (1998) 1229-1234
121. Yin Y., et al. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 123 1 (2007) 27-38
122. Jin C., et al. Cellular uptake and radiosensitisation off SR-2508 loaded PLGA nanoparticles. J. Nanoparticle Res. 10 (2008) 1045
123. Sheng Y., et al. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J. Mater. Sci. Mater. Med. 20 9 (2009) 1881-1891
124. Gomez-Gaete C., et al. Dexamethasone acetate encapsulation into Trojan particles. J. Control. Release 128 1 (2008) 41-49
125. Sonaje K., et al. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm. Res. 24 5 (2007) 899-908
126. Mainardes R.M., et al. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 98 1 (2009) 257-267
127. Zheng D., et al. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim. Biophys. Sin. (Shanghai) 41 7 (2009) 578-587
128. Prabu P., Dharmaraj A.A.C.N., Khil M.S., Park S.Y., and Kim H.Y. Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. J. Biomed. Mater. Res. 90A (2008) 1128
129. Choubey A.K.B.A.J. Release study of sulphamethoxazole controlled by swelling of gelatin nanoparticles and drug-biopolymer interaction. J. Macromol. Sci. 42 (2005) 253
130. Bhattarai N., et al. Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery. Int. J. Nanomed. 1 2 (2006) 181
131. Shozo Miyazaki A.T., and Wataru K. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J. Pharm. Pharmaceut. Sci. 6 2 (2003) 238